Non-transferrin-bound iron transporters

Free Radical Biology and Medicine

Volumn 133, Issue , 2019, Pages 101-111

  Knutson, Mitchell D ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Hereditary hemochromatosis; Labile plasma iron; Thalassemia major; ZIP14, L type calcium channels

Indexed keywords

CALCIUM CHANNEL L TYPE; FERROPORTIN; IRON; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; NON TRANSFERRIN BOUND IRON; TRANSFERRIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; UNCLASSIFIED DRUG; ZIP14 PROTEIN; ZIP8 PROTEIN; CALCIUM CHANNEL N TYPE; CATION TRANSPORT PROTEIN; DMRT1 PROTEIN; SLC39A14 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; ZIP8 PROTEIN, HUMAN;

BLOOD LEVEL; BRAIN; CELL TRANSPORT; ENDOCRINE GLAND; HUMAN; IN VIVO STUDY; IRON OVERLOAD; IRON TRANSPORT; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVIEW; BETA THALASSEMIA; GENETICS; HEMOCHROMATOSIS; ION TRANSPORT; LIVER; METABOLISM; PATHOLOGY;

BETA-THALASSEMIA; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, N-TYPE; CATION TRANSPORT PROTEINS; HEMOCHROMATOSIS; HUMANS; ION TRANSPORT; IRON; IRON OVERLOAD; LIVER; TRANSCRIPTION FACTORS; TRANSFERRIN; TRPC6 CATION CHANNEL;

EID: 85055277550     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2018.10.413     Document Type: Review

References (172)

1. Brissot, P., Ropert, M., Le Lan, C., Loreal, O., Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim. Biophys. Acta 1820:3 (2012), 403–410.
2. Cabantchik, Z.I., Labile iron in cells and body fluids: physiology, pathology, and pharmacology. Front. Pharmacol., 5, 2014, 45.
3. Esposito, B.P., Breuer, W., Sirankapracha, P., Pootrakul, P., Hershko, C., Cabantchik, Z.I., Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 102:7 (2003), 2670–2677.
4. Evans, R.W., Rafique, R., Zarea, A., Rapisarda, C., Cammack, R., Evans, P.J., Porter, J.B., Hider, R.C., Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera. J. Biol. Inorg. Chem. 13:1 (2008), 57–74.
5. Hider, R.C., Silva, A.M., Podinovskaia, M., Ma, Y., Monitoring the efficiency of iron chelation therapy: the potential of nontransferrin-bound iron. Ann. N. Y. Acad. Sci. 1202 (2010), 94–99.
6. Grootveld, M., Bell, J.D., Halliwell, B., Aruoma, O.I., Bomford, A., Sadler, P.J., Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. J. Biol. Chem. 264:8 (1989), 4417–4422.
7. Porter, J.B., Walter, P.B., Neumayr, L.D., Evans, P., Bansal, S., Garbowski, M., Weyhmiller, M.G., Harmatz, P.R., Wood, J.C., Miller, J.L., Byrnes, C., Weiss, G., Seifert, M., Grosse, R., Grabowski, D., Schmidt, A., Fischer, R., Nielsen, P., Niemeyer, C., Vichinsky, E., Mechanisms of plasma non-transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients. Br. J. Haematol. 167:5 (2014), 692–696.
8. de Swart, L., Hendriks, J.C., van der Vorm, L.N., Cabantchik, Z.I., Evans, P.J., Hod, E.A., Brittenham, G.M., Furman, Y., Wojczyk, B., Janssen, M.C., Porter, J.B., Mattijssen, V.E., Biemond, B.J., MacKenzie, M.A., Origa, R., Galanello, R., Hider, R.C., Swinkels, D.W., Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders. Haematologica 101:1 (2016), 38–45.
9. Beard, J.L., Wiesinger, J.A., Li, N., Connor, J.R., Brain iron uptake in hypotransferrinemic mice: influence of systemic iron status. J. Neurosci. Res. 79:1–2 (2005), 254–261.
10. Bradbury, M.W., Raja, K., Ueda, F., Contrasting uptakes of 59Fe into spleen, liver, kidney and some other soft tissues in normal and hypotransferrinaemic mice. Influence of an antibody against the transferrin receptor. Biochem. Pharmacol. 47:6 (1994), 969–974.
11. Craven, C.M., Alexander, J., Eldridge, M., Kushner, J.P., Bernstein, S., Kaplan, J., Tissue distribution and clearance kinetics of non-transferrin-bound iron in the hypotransferrinemic mouse: a rodent model for hemochromatosis. Proc. Natl. Acad. Sci. USA 84:10 (1987), 3457–3461.
12. Jenkitkasemwong, S., Wang, C.Y., Coffey, R., Zhang, W., Chan, A., Biel, T., Kim, J.S., Hojyo, S., Fukada, T., Knutson, M.D., SLC39A14 is required for the development of hepatocellular iron overload in murine models of hereditary hemochromatosis. Cell Metab. 22:1 (2015), 138–150.
13. Jenkitkasemwong, S., Wang, C.Y., Knutson, M.D., Measurement of transferrin- and non-transferrin-bound iron uptake by mouse tissues. Bio Protoc., 6(17), 2016.
14. Wang, C.Y., Knutson, M.D., Hepatocyte divalent metal-ion transporter-1 is dispensable for hepatic iron accumulation and non-transferrin-bound iron uptake in mice. Hepatology 58:2 (2013), 788–798.
15. Wheby, M.S., Jones, L.G., Role of transferrin in iron absorption. J. Clin. Investig. 42 (1963), 1007–1016.
16. Bernstein, S.E., Hereditary hypotransferrinemia with hemosiderosis, a murine disorder resembling human atransferrinemia. J. Lab. Clin. Med. 110:6 (1987), 690–705.
17. Dickinson, T.K., Devenyi, A.G., Connor, J.R., Distribution of injected iron 59 and manganese 54 in hypotransferrinemic mice. J. Lab. Clin. Med. 128:3 (1996), 270–278.
18. Brissot, P., Wright, T.L., Ma, W.L., Weisiger, R.A., Efficient clearance of non-transferrin-bound iron by rat liver. implications for hepatic iron loading in iron overload states. J. Clin. Investig. 76:4 (1985), 1463–1470.
19. Wright, T.L., Brissot, P., Ma, W.L., Weisiger, R.A., Characterization of non-transferrin-bound iron clearance by rat liver. J. Biol. Chem. 261:23 (1986), 10909–10914.
20. Wheby, M.S., Umpierre, G., Effect of Transferrin Saturation on Iron Absorption in Man. N. Engl. J. Med. 271 (1964), 1391–1395.
21. Fawwaz, R.A., Winchell, H.S., Pollycove, M., Sargent, T., Hepatic iron deposition in humans. I. First-pass hepatic deposition of intestinally absorbed iron in patients with low plasma latent iron-binding capacity. Blood 30:4 (1967), 417–424.
22. Kishimoto, M., Endo, H., Hagiwara, S., Miwa, A., Noda, M., Immunohistochemical findings in the pancreatic islets of a patient with transfusional iron overload and diabetes: case report. J. Med. Investig. 57:3-4 (2010), 345–349.
23. Lu, J.P., Hayashi, K., Selective iron deposition in pancreatic islet B cells of transfusional iron-overloaded autopsy cases. Pathol. Int. 44:3 (1994), 194–199.
24. Suda, K., Hemosiderin deposition in the pancreas. Arch. Pathol. Lab. Med. 109:11 (1985), 996–999.
25. Altamura, S., Kessler, R., Grone, H.J., Gretz, N., Hentze, M.W., Galy, B., Muckenthaler, M.U., Resistance of ferroportin to hepcidin binding causes exocrine pancreatic failure and fatal iron overload. Cell Metab. 20:2 (2014), 359–367.
26. Nick, H., Allegrini, P.R., Fozard, L., Junker, U., Rojkjaer, L., Salie, R., Niederkofler, V., O'Reilly, T., Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis. Exp. Biol. Med. (Maywood) 234:5 (2009), 492–503.
27. Ramey, G., Faye, A., Durel, B., Viollet, B., Vaulont, S., Iron overload in Hepc1(-/-) mice is not impairing glucose homeostasis. FEBS Lett. 581:5 (2007), 1053–1057.
28. Simpson, R.J., Deenmamode, J., McKie, A.T., Raja, K.B., Salisbury, J.R., Iancu, T.C., Peters, T.J., Time-course of iron overload and biochemical, histopathological and ultrastructural evidence of pancreatic damage in hypotransferrinaemic mice. Clin. Sci. (Lond.) 93:5 (1997), 453–462.
29. Tripathi, A.K., Karmakar, S., Asthana, A., Ashok, A., Desai, V., Baksi, S., Singh, N., Transport of non-transferrin bound iron to the brain: implications for Alzheimer's disease. J. Alzheimers Dis. 58:4 (2017), 1109–1119.
30. Moulouel, B., Houamel, D., Delaby, C., Tchernitchko, D., Vaulont, S., Letteron, P., Thibaudeau, O., Puy, H., Gouya, L., Beaumont, C., Karim, Z., Hepcidin regulates intrarenal iron handling at the distal nephron. Kidney Int. 84:4 (2013), 756–766.
31. Wareing, M., Ferguson, C.J., Green, R., Riccardi, D., Smith, C.P., In vivo characterization of renal iron transport in the anaesthetized rat. J. Physiol. 524:Pt 2 (2000), 581–586.
32. Link, G., Athias, P., Grynberg, A., Pinson, A., Hershko, C., Effect of iron loading on transmembrane potential, contraction, and automaticity of rat ventricular muscle cells in culture. J. Lab. Clin. Med. 113:1 (1989), 103–111.
33. Iancu, T.C., Shiloh, H., Link, G., Bauminger, E.R., Pinson, A., Hershko, C., Ultrastructural pathology of iron-loaded rat myocardial cells in culture. Br. J. Exp. Pathol. 68:1 (1987), 53–65.
34. Liu, Y., Parkes, J.G., Templeton, D.M., Differential accumulation of non-transferrin-bound iron by cardiac myocytes and fibroblasts. J. Mol. Cell. Cardiol. 35:5 (2003), 505–514.
35. Parkes, J.G., Hussain, R.A., Olivieri, N.F., Templeton, D.M., Effects of iron loading on uptake, speciation, and chelation of iron in cultured myocardial cells. J. Lab. Clin. Med. 122:1 (1993), 36–47.
36. Randell, E.W., Parkes, J.G., Olivieri, N.F., Templeton, D.M., Uptake of non-transferrin-bound iron by both reductive and nonreductive processes is modulated by intracellular iron. J. Biol. Chem. 269:23 (1994), 16046–16053.
37. Subramaniam, V.N., McDonald, C.J., Ostini, L., Lusby, P.E., Wockner, L.F., Ramm, G.A., Wallace, D.F., Hepatic iron deposition does not predict extrahepatic iron loading in mouse models of hereditary hemochromatosis. Am. J. Pathol. 181:4 (2012), 1173–1179.
38. Noetzli, L.J., Papudesi, J., Coates, T.D., Wood, J.C., Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood 114:19 (2009), 4021–4026.
39. Herrera, C., Pettiglio, M.A., Bartnikas, T.B., Investigating the role of transferrin in the distribution of iron, manganese, copper, and zinc. J. Biol. Inorg. Chem. 19:6 (2014), 869–877.
40. De Sanctis, V., Eleftheriou, A., Malaventura, C., Thalassaemia International Federation Study Group on. Endocrine complications in, prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr. Endocrinol. Rev. 2:Suppl 2 (2004), S249–S255.
41. Rivard, S.R., Mura, C., Simard, H., Simard, R., Grimard, D., Le Gac, G., Raguenes, O., Ferec, C., De Braekeleer, M., Clinical and molecular aspects of juvenile hemochromatosis in Saguenay-Lac-Saint-Jean (Quebec, canada). Blood Cells Mol. Dis. 26:1 (2000), 10–14.
42. Huang, K.E., Mittelman, S.D., Coates, T.D., Geffner, M.E., Wood, J.C., A significant proportion of thalassemia major patients have adrenal insufficiency detectable on provocative testing. J. Pediatr. Hematol. Oncol. 37:1 (2015), 54–59.
43. Coffey, R., Knutson, M.D., The plasma membrane metal-ion transporter ZIP14 contributes to nontransferrin-bound iron uptake by human beta-cells. Am. J. Physiol. Cell Physiol. 312:2 (2017), C169–C175.
44. Chatterjee, R., Bajoria, R., Critical appraisal of growth retardation and pubertal disturbances in thalassemia. Ann. N. Y. Acad. Sci. 1202 (2010), 100–114.
45. Bergeron, C., Kovacs, K., Pituitary siderosis. A histologic, immunocytologic, and ultrastructural study. Am. J. Pathol. 93:2 (1978), 295–309.
46. Noetzli, L.J., Panigrahy, A., Mittelman, S.D., Hyderi, A., Dongelyan, A., Coates, T.D., Wood, J.C., Pituitary iron and volume predict hypogonadism in transfusional iron overload. Am. J. Hematol. 87:2 (2012), 167–171.
47. Soliman, A.T., Yafei, F. Al, Al-Naimi, L., Almarri, N., Sabt, A., Yassin, M., Sanctis, V. De, Longitudinal study on thyroid function in patients with thalassemia major: high incidence of central hypothyroidism by 18 years. Indian J. Endocrinol. Metab. 17:6 (2013), 1090–1095.
48. Kaplan, J., Craven, C., Alexander, J., Kushner, J., Lamb, J., Bernstein, S., Regulation of the distribution of tissue iron. Lessons learned from the hypotransferrinemic mouse. Ann. N. Y. Acad. Sci. 526 (1988), 124–135.
49. Heidari, M., Johnstone, D.M., Bassett, B., Graham, R.M., Chua, A.C., House, M.J., Collingwood, J.F., Bettencourt, C., Houlden, H., Ryten, M., Olynyk, J.K., Trinder, D., Milward, E.A., Brain iron accumulation affects myelin-related molecular systems implicated in a rare neurogenetic disease family with neuropsychiatric features. Mol. Psychiatry 21:11 (2016), 1599–1607.
50. Metafratzi, Z., Argyropoulou, M.I., Kiortsis, D.N., Tsampoulas, C., Chaliassos, N., Efremidis, S.C., T(2) relaxation rate of basal ganglia and cortex in patients with beta-thalassaemia major. Br. J. Radiol. 74:881 (2001), 407–410.
51. Qiu, D., Chan, G.C., Chu, J., Chan, Q., Ha, S.Y., Moseley, M.E., Khong, P.L., MR quantitative susceptibility imaging for the evaluation of iron loading in the brains of patients with beta-thalassemia major. AJNR Am. J. Neuroradiol. 35:6 (2014), 1085–1090.
52. Ueda, F., Raja, K.B., Simpson, R.J., Trowbridge, I.S., Bradbury, M.W., Rate of 59Fe uptake into brain and cerebrospinal fluid and the influence thereon of antibodies against the transferrin receptor. J. Neurochem. 60:1 (1993), 106–113.
53. Takeda, A., Takatsuka, K., Sotogaku, N., Oku, N., Influence of iron-saturation of plasma transferrin in iron distribution in the brain. Neurochem. Int. 41:4 (2002), 223–228.
54. Bradbury, M.W., Transport of iron in the blood-brain-cerebrospinal fluid system. J. Neurochem. 69:2 (1997), 443–454.
55. Moos, T., Immunohistochemical localization of intraneuronal transferrin receptor immunoreactivity in the adult mouse central nervous system. J. Comp. Neurol. 375:4 (1996), 675–692.
56. Bishop, G.M., Scheiber, I.F., Dringen, R., Robinson, S.R., Synergistic accumulation of iron and zinc by cultured astrocytes. J. Neural Transm. (Vienna) 117:7 (2010), 809–817.
57. Hoepken, H.H., Korten, T., Robinson, S.R., Dringen, R., Iron accumulation, iron-mediated toxicity and altered levels of ferritin and transferrin receptor in cultured astrocytes during incubation with ferric ammonium citrate. J. Neurochem. 88:5 (2004), 1194–1202.
58. Jeong, S.Y., David, S., Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J. Biol. Chem. 278:29 (2003), 27144–27148.
59. Lane, D.J., Robinson, S.R., Czerwinska, H., Bishop, G.M., Lawen, A., Two routes of iron accumulation in astrocytes: ascorbate-dependent ferrous iron uptake via the divalent metal transporter (DMT1) plus an independent route for ferric iron. Biochem. J. 432:1 (2010), 123–132.
60. Pelizzoni, I., Zacchetti, D., Campanella, A., Grohovaz, F., Codazzi, F., Iron uptake in quiescent and inflammation-activated astrocytes: a potentially neuroprotective control of iron burden. Biochim. Biophys. Acta 1832:8 (2013), 1326–1333.
61. Qian, Z.M., Liao, Q.K., To, Y., Ke, Y., Tsoi, Y.K., Wang, G.F., Ho, K.P., Transferrin-bound and transferrin free iron uptake by cultured rat astrocytes. Cell. Mol. Biol. (Noisy-Le.-Grand.) 46:3 (2000), 541–548.
62. Riemer, J., Hoepken, H.H., Czerwinska, H., Robinson, S.R., Dringen, R., Colorimetric ferrozine-based assay for the quantitation of iron in cultured cells. Anal. Biochem. 331:2 (2004), 370–375.
63. Tulpule, K., Robinson, S.R., Bishop, G.M., Dringen, R., Uptake of ferrous iron by cultured rat astrocytes. J. Neurosci. Res. 88:3 (2010), 563–571.
64. Dringen, R., Bishop, G.M., Koeppe, M., Dang, T.N., Robinson, S.R., The pivotal role of astrocytes in the metabolism of iron in the brain. Neurochem. Res. 32:11 (2007), 1884–1890.
65. Cheah, J.H., Kim, S.F., Hester, L.D., Clancy, K.W., Patterson, S.E. 3rd, Papadopoulos, V., Snyder, S.H., NMDA receptor-nitric oxide transmission mediates neuronal iron homeostasis via the GTPase Dexras1. Neuron 51:4 (2006), 431–440.
66. Du, F., Fan, M., Gong, Q., Zhu, L.L., Zhu, Z.J., Lu, L., Ke, Y., Effects of hypoxic preconditioning on the expression of iron influx and efflux proteins in primary neuron culture. Neurochem. Int. 60:4 (2012), 335–343.
67. Gaasch, J.A., Geldenhuys, W.J., Lockman, P.R., Allen, D.D., Van der Schyf, C.J., Voltage-gated calcium channels provide an alternate route for iron uptake in neuronal cell cultures. Neurochem. Res. 32:10 (2007), 1686–1693.
68. Ji, C., Kosman, D.J., Molecular mechanisms of non-transferrin-bound and transferring-bound iron uptake in primary hippocampal neurons. J. Neurochem. 133:5 (2015), 668–683.
69. Pelizzoni, I., Macco, R., Morini, M.F., Zacchetti, D., Grohovaz, F., Codazzi, F., Iron handling in hippocampal neurons: activity-dependent iron entry and mitochondria-mediated neurotoxicity. Aging Cell 10:1 (2011), 172–183.
70. Pelizzoni, I., Zacchetti, D., Smith, C.P., Grohovaz, F., Codazzi, F., Expression of divalent metal transporter 1 in primary hippocampal neurons: reconsidering its role in non-transferrin-bound iron influx. J. Neurochem. 120:2 (2012), 269–278.
71. SanMartin, C.D., Paula-Lima, A.C., Hidalgo, C., Nunez, M.T., Sub-lethal levels of amyloid beta-peptide oligomers decrease non-transferrin-bound iron uptake and do not potentiate iron toxicity in primary hippocampal neurons. Biometals 25:4 (2012), 805–813.
72. Bishop, G.M., Dang, T.N., Dringen, R., Robinson, S.R., Accumulation of non-transferrin-bound iron by neurons, astrocytes, and microglia. Neurotox. Res. 19:3 (2011), 443–451.
73. McCarthy, R.C., Sosa, J.C., Gardeck, A.M., Baez, A.S., Lee, C.H., Wessling-Resnick, M., Inflammation-induced iron transport and metabolism by brain microglia. J. Biol. Chem. 293:20 (2018), 7853–7863.
74. Jeong, J., Eide, D.J., The SLC39 family of zinc transporters. Mol. Asp. Med. 34:2–3 (2013), 612–619.
75. Eng, B.H., Guerinot, M.L., Eide, D., Saier, M.H. Jr., Sequence analyses and phylogenetic characterization of the ZIP family of metal ion transport proteins. J. Membr. Biol. 166:1 (1998), 1–7.
76. Taylor, K.M., Morgan, H.E., Johnson, A., Nicholson, R.I., Structure-function analysis of a novel member of the LIV-1 subfamily of zinc transporters, ZIP14. FEBS Lett. 579:2 (2005), 427–432.
77. Wang, C.Y., Jenkitkasemwong, S., Duarte, S., Sparkman, B.K., Shawki, A., Mackenzie, B., Knutson, M.D., ZIP8 is an iron and zinc transporter whose cell-surface expression is up-regulated by cellular iron loading. J. Biol. Chem. 287:41 (2012), 34032–34043.
78. Liuzzi, J.P., Aydemir, F., Nam, H., Knutson, M.D., Cousins, R.J., Zip14 (Slc39a14) mediates non-transferrin-bound iron uptake into cells. Proc. Natl. Acad. Sci. Usa. 103:37 (2006), 13612–13617.
79. Eide, D., Broderius, M., Fett, J., Guerinot, M.L., A novel iron-regulated metal transporter from plants identified by functional expression in yeast. Proc. Natl. Acad. Sci. USA 93:11 (1996), 5624–5628.
80. Pinilla-Tenas, J.J., Sparkman, B.K., Shawki, A., Illing, A.C., Mitchell, C.J., Zhao, N., Liuzzi, J.P., Cousins, R.J., Knutson, M.D., Mackenzie, B., Zip14 is a complex broad-scope metal-ion transporter whose functional properties support roles in the cellular uptake of zinc and nontransferrin-bound iron. Am. J. Physiol. Cell Physiol. 301:4 (2011), C862–C871.
81. Nam, H., Wang, C.Y., Zhang, L., Zhang, W., Hojyo, S., Fukada, T., Knutson, M.D., ZIP14 and DMT1 in the liver, pancreas, and heart are differentially regulated by iron deficiency and overload: implications for tissue iron uptake in iron-related disorders. Haematologica 98:7 (2013), 1049–1057.
82. Bonilla, S., Prozialeck, J.D., Malladi, P., Pan, X., Yu, S., Melin-Aldana, H., Whitington, P.F., Neonatal iron overload and tissue siderosis due to gestational alloimmune liver disease. J. Hepatol. 56:6 (2012), 1351–1355.
83. Nam, H., Knutson, M.D., Effect of dietary iron deficiency and overload on the expression of ZIP metal-ion transporters in rat liver. Biometals 25:1 (2012), 115–124.
84. Zhao, N., Zhang, A.S., Worthen, C., Knutson, M.D., Enns, C.A., An iron-regulated and glycosylation-dependent proteasomal degradation pathway for the plasma membrane metal transporter ZIP14. Proc. Natl. Acad. Sci. USA 111:25 (2014), 9175–9180.
85. Tuschl, K., Meyer, E., Valdivia, L.E., Zhao, N., Dadswell, C., Abdul-Sada, A., Hung, C.Y., Simpson, M.A., Chong, W.K., Jacques, T.S., Woltjer, R.L., Eaton, S., Gregory, A., Sanford, L., Kara, E., Houlden, H., Cuno, S.M., Prokisch, H., Valletta, L., Tiranti, V., Younis, R., Maher, E.R., Spencer, J., Straatman-Iwanowska, A., Gissen, P., Selim, L.A., Pintos-Morell, G., Coroleu-Lletget, W., Mohammad, S.S., Yoganathan, S., Dale, R.C., Thomas, M., Rihel, J., Bodamer, O.A., Enns, C.A., Hayflick, S.J., Clayton, P.T., Mills, P.B., Kurian, M.A., Wilson, S.W., Mutations in SLC39A14 disrupt manganese homeostasis and cause childhood-onset parkinsonism-dystonia. Nat. Commun., 7, 2016, 11601.
86. Jenkitkasemwong, S., Akinyode, A., Paulus, E., Weiskirchen, R., Hojyo, S., Fukada, T., Giraldo, G., Schrier, J., Garcia, A., Janus, C., Giasson, B., Knutson, M.D., SLC39A14 deficiency alters manganese homeostasis and excretion resulting in brain manganese accumulation and motor deficits in mice. Proc. Natl. Acad. Sci. USA 115:8 (2018), E1769–E1778.
87. Xin, Y., Gao, H., Wang, J., Qiang, Y., Imam, M.U., Li, Y., Wang, J., Zhang, R., Zhang, H., Yu, Y., Wang, H., Luo, H., Shi, C., Xu, Y., Hojyo, S., Fukada, T., Min, J., Wang, F., Manganese transporter Slc39a14 deficiency revealed its key role in maintaining manganese homeostasis in mice. Cell Discov., 3, 2017, 17025.
88. Aydemir, T.B., Kim, M.H., Kim, J., Colon-Perez, L.M., Banan, G., Mareci, T.H., Febo, M., Cousins, R.J., Metal transporter Zip14 (Slc39a14) deletion in mice increases manganese deposition and produces neurotoxic signatures and diminished motor activity. J. Neurosci. 37:25 (2017), 5996–6006.
89. Zimelman, A.P., Zimmerman, H.J., McLean, R., Weintraub, L.R., Effect of iron saturation of transferrin on hepatic iron uptake: an in vitro study. Gastroenterology 72:1 (1977), 129–131.
90. Clark, M.G., Partick, E.J., Patten, G.S., Crane, F.L., Low, H., Grebing, C., Evidence for the extracellular reduction of ferricyanide by rat liver. A trans-plasma membrane redox system. Biochem. J. 200:3 (1981), 565–572.
91. Zhao, N., Gao, J., Enns, C.A., Knutson, M.D., ZRT/IRT-like protein 14 (ZIP14) promotes the cellular assimilation of iron from transferrin. J. Biol. Chem. 285:42 (2010), 32141–32150.
92. Illing, A.C., Shawki, A., Cunningham, C.L., Mackenzie, B., Substrate profile and metal-ion selectivity of human divalent metal-ion transporter-1. J. Biol. Chem. 287:36 (2012), 30485–30496.
93. Jenkitkasemwong, S., Wang, C.Y., Mackenzie, B., Knutson, M.D., Physiologic implications of metal-ion transport by ZIP14 and ZIP8. Biometals 25:4 (2012), 643–655.
94. Taylor, K.M., Morgan, H.E., Smart, K., Zahari, N.M., Pumford, S., Ellis, I.O., Robertson, J.F., Nicholson, R.I., The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer. Mol. Med. 13:7–8 (2007), 396–406.
95. Lin, W., Vann, D.R., Doulias, P.T., Wang, T., Landesberg, G., Li, X., Ricciotti, E., Scalia, R., He, M., Hand, N.J., Rader, D.J., Hepatic metal ion transporter ZIP8 regulates manganese homeostasis and manganese-dependent enzyme activity. J. Clin. Investig. 127:6 (2017), 2407–2417.
96. Galvez-Peralta, M., He, L., Jorge-Nebert, L.F., Wang, B., Miller, M.L., Eppert, B.L., Afton, S., Nebert, D.W., ZIP8 zinc transporter: indispensable role for both multiple-organ organogenesis and hematopoiesis in utero. PLoS One, 7(5), 2012, e36055.
97. Boycott, K.M., Beaulieu, C.L., Kernohan, K.D., Gebril, O.H., Mhanni, A., Chudley, A.E., Redl, D., Qin, W., Hampson, S., Kury, S., Tetreault, M., Puffenberger, E.G., Scott, J.N., Bezieau, S., Reis, A., Uebe, S., Schumacher, J., Hegele, R.A., McLeod, D.R., Galvez-Peralta, M., Majewski, J., Ramaekers, V.T., Care4Rare Canada, C., Nebert, D.W., Innes, A.M., Parboosingh, J.S., Abou Jamra, R., Autosomal-recessive intellectual disability with cerebellar atrophy syndrome caused by mutation of the manganese and zinc transporter gene SLC39A8. Am. J. Hum. Genet. 97:6 (2015), 886–893.
98. Park, J.H., Hogrebe, M., Gruneberg, M., DuChesne, I., von der Heiden, A.L., Reunert, J., Schlingmann, K.P., Boycott, K.M., Beaulieu, C.L., Mhanni, A.A., Innes, A.M., Hortnagel, K., Biskup, S., Gleixner, E.M., Kurlemann, G., Fiedler, B., Omran, H., Rutsch, F., Wada, Y., Tsiakas, K., Santer, R., Nebert, D.W., Rust, S., Marquardt, T., SLC39A8 deficiency: a disorder of manganese transport and glycosylation. Am. J. Hum. Genet. 97:6 (2015), 894–903.
99. Martines, A.M., Masereeuw, R., Tjalsma, H., Hoenderop, J.G., Wetzels, J.F., Swinkels, D.W., Iron metabolism in the pathogenesis of iron-induced kidney injury. Nat. Rev. Nephrol. 9:7 (2013), 385–398.
100. Thevenod, F., Wolff, N.A., Iron transport in the kidney: implications for physiology and cadmium nephrotoxicity. Metallomics 8:1 (2016), 17–42.
101. Raaij, S.V., Swelm, R.V., Bouman, K., Cliteur, M., Heuvel, M.V.D., Pertijs, J., Patel, D., Bass, P., Goor, H.V., Unwin, R., Srai, S.K., Swinkels, D., Tubular iron deposition and iron handling proteins in human healthy kidney and chronic kidney disease. Sci. Rep., 8(1), 2018, 9353.
102. Baumann, B., Sterling, J., Song, Y., Song, D., Fruttiger, M., Gillies, M., Shen, W., Dunaief, J.L., Conditional muller cell ablation leads to retinal iron accumulation. Investig. Ophthalmol. Vis. Sci. 58:10 (2017), 4223–4234.
103. Sterling, J., Guttha, S., Song, Y., Song, D., Hadziahmetovic, M., Dunaief, J.L., Iron importers Zip8 and Zip14 are expressed in retina and regulated by retinal iron levels. Exp. Eye Res. 155 (2017), 15–23.
104. Fleming, M.D., Trenor, C.C. 3rd, Su, M.A., Foernzler, D., Beier, D.R., Dietrich, W.F., Andrews, N.C., Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat. Genet. 16:4 (1997), 383–386.
105. Gunshin, H., Mackenzie, B., Berger, U.V., Gunshin, Y., Romero, M.F., Boron, W.F., Nussberger, S., Gollan, J.L., Hediger, M.A., Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 388:6641 (1997), 482–488.
106. Montalbetti, N., Simonin, A., Kovacs, G., Hediger, M.A., Mammalian iron transporters: families SLC11 and SLC40. Mol. Asp. Med. 34:2–3 (2013), 270–287.
107. Ehrnstorfer, I.A., Geertsma, E.R., Pardon, E., Steyaert, J., Dutzler, R., Crystal structure of a SLC11 (NRAMP) transporter reveals the basis for transition-metal ion transport. Nat. Struct. Mol. Biol. 21:11 (2014), 990–996.
108. Ehrnstorfer, I.A., Manatschal, C., Arnold, F.M., Laederach, J., Dutzler, R., Structural and mechanistic basis of proton-coupled metal ion transport in the SLC11/NRAMP family. Nat. Commun., 8, 2017, 14033.
109. Gunshin, H., Fujiwara, Y., Custodio, A.O., Direnzo, C., Robine, S., Andrews, N.C., Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver. J. Clin. Investig. 115:5 (2005), 1258–1266.
110. Shawki, A., Anthony, S.R., Nose, Y., Engevik, M.A., Niespodzany, E.J., Barrientos, T., Ohrvik, H., Worrell, R.T., Thiele, D.J., Mackenzie, B., Intestinal DMT1 is critical for iron absorption in the mouse but is not required for the absorption of copper or manganese. Am. J. Physiol. Gastrointest. Liver Physiol. 309:8 (2015), G635–G647.
111. McKie, A.T., Barrow, D., Latunde-Dada, G.O., Rolfs, A., Sager, G., Mudaly, E., Mudaly, M., Richardson, C., Barlow, D., Bomford, A., Peters, T.J., Raja, K.B., Shirali, S., Hediger, M.A., Farzaneh, F., Simpson, R.J., An iron-regulated ferric reductase associated with the absorption of dietary iron. Science 291:5509 (2001), 1755–1759.
112. Garrick, L.M., Dolan, K.G., Romano, M.A., Garrick, M.D., Non-transferrin-bound iron uptake in Belgrade and normal rat erythroid cells. J. Cell. Physiol. 178:3 (1999), 349–358.
113. Hodgson, L.L., Quail, E.A., Morgan, E.H., Iron transport mechanisms in reticulocytes and mature erythrocytes. J. Cell. Physiol. 162:2 (1995), 181–190.
114. Mackenzie, B., Ujwal, M.L., Chang, M.H., Romero, M.F., Hediger, M.A., Divalent metal-ion transporter DMT1 mediates both H+ -coupled Fe2+ transport and uncoupled fluxes. Pflug. Arch. 451:4 (2006), 544–558.
115. Shawki, A., Knight, P.B., Maliken, B.D., Niespodzany, E.J., Mackenzie, B., H(+)-coupled divalent metal-ion transporter-1: functional properties, physiological roles and therapeutics. Curr. Top. Membr. 70 (2012), 169–214.
116. Tabuchi, M., Yoshimori, T., Yamaguchi, K., Yoshida, T., Kishi, F., Human NRAMP2/DMT1, which mediates iron transport across endosomal membranes, is localized to late endosomes and lysosomes in HEp-2 cells. J. Biol. Chem. 275:29 (2000), 22220–22228.
117. Yanatori, I., Yasui, Y., Tabuchi, M., Kishi, F., Chaperone protein involved in transmembrane transport of iron. Biochem. J. 462:1 (2014), 25–37.
118. Canonne-Hergaux, F., Gros, P., Expression of the iron transporter DMT1 in kidney from normal and anemic mk mice. Kidney Int. 62:1 (2002), 147–156.
119. Ferguson, C.J., Wareing, M., Ward, D.T., Green, R., Smith, C.P., Riccardi, D., Cellular localization of divalent metal transporter DMT-1 in rat kidney. Am. J. Physiol. Ren. Physiol. 280:5 (2001), F803–F814.
120. Kozyraki, R., Fyfe, J., Verroust, P.J., Jacobsen, C., Dautry-Varsat, A., Gburek, J., Willnow, T.E., Christensen, E.I., Moestrup, S.K., Megalin-dependent cubilin-mediated endocytosis is a major pathway for the apical uptake of transferrin in polarized epithelia. Proc. Natl. Acad. Sci. USA 98:22 (2001), 12491–12496.
121. Veuthey, T., Hoffmann, D., Vaidya, V.S., Wessling-Resnick, M., Impaired renal function and development in Belgrade rats. Am. J. Physiol. Ren. Physiol. 306:3 (2014), F333–F343.
122. Ferguson, C.J., Wareing, M., Delannoy, M., Fenton, R., McLarnon, S.J., Ashton, N., Cox, A.G., McMahon, R.F., Garrick, L.M., Green, R., Smith, C.P., Riccardi, D., Iron handling and gene expression of the divalent metal transporter, DMT1, in the kidney of the anemic Belgrade (b) rat. Kidney Int. 64:5 (2003), 1755–1764.
123. Ludwiczek, S., Theurl, I., Muckenthaler, M.U., Jakab, M., Mair, S.M., Theurl, M., Kiss, J., Paulmichl, M., Hentze, M.W., Ritter, M., Weiss, G., Ca2+ channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1. Nat. Med. 13:4 (2007), 448–454.
124. Mackenzie, B., Shawki, A., Ghio, A.J., Stonehuerner, J.D., Zhao, L., Ghadersohi, S., Garrick, L.M., Garrick, M.D., Calcium-channel blockers do not affect iron transport mediated by divalent metal-ion transporter-1. Blood 115:20 (2010), 4148–4149.
125. Ke, Y., Chen, Y.Y., Chang, Y.Z., Duan, X.L., Ho, K.P., Jiang, D.H., Wang, K., Qian, Z.M., Post-transcriptional expression of DMT1 in the heart of rat. J. Cell. Physiol. 196:1 (2003), 124–130.
126. Zhao, N., Sun, Z., Mao, Y., Hang, P., Jiang, X., Sun, L., Zhao, J., Du, Z., Myocardial iron metabolism in the regulation of cardiovascular diseases in rats. Cell. Physiol. Biochem. 25:6 (2010), 587–594.
127. Wetli, H.A., Buckett, P.D., Wessling-Resnick, M., Small-molecule screening identifies the selanazal drug ebselen as a potent inhibitor of DMT1-mediated iron uptake. Chem. Biol. 13:9 (2006), 965–972.
128. Davis, M.T., Bartfay, W.J., Ebselen decreases oxygen free radical production and iron concentrations in the hearts of chronically iron-overloaded mice. Biol. Res. Nurs. 6:1 (2004), 37–45.
129. Kumfu, S., Chattipakorn, S., Chinda, K., Fucharoen, S., Chattipakorn, N., T-type calcium channel blockade improves survival and cardiovascular function in thalassemic mice. Eur. J. Haematol. 88:6 (2012), 535–548.
130. Rice, M.E., Russo-Menna, I., Differential compartmentalization of brain ascorbate and glutathione between neurons and glia. Neuroscience 82:4 (1998), 1213–1223.
131. Buckett, P.D., Wessling-Resnick, M., Small molecule inhibitors of divalent metal transporter-1. Am. J. Physiol. Gastrointest. Liver Physiol. 296:4 (2009), G798–G804.
132. Codazzi, F., Pelizzoni, I., Zacchetti, D., Grohovaz, F., Iron entry in neurons and astrocytes: a link with synaptic activity. Front. Mol. Neurosci., 8, 2015, 18.
133. Zhang, C.W., Tai, Y.K., Chai, B.H., Chew, K.C.M., Ang, E.T., Tsang, F., Tan, B.W.Q., Hong, E.T.E., Asad, A.B.A., Chuang, K.H., Lim, K.L., Soong, T.W., Transgenic mice overexpressing the divalent metal transporter 1 exhibit iron accumulation and enhanced Parkin expression in the brain. Neuromol. Med. 19:2–3 (2017), 375–386.
134. Striessnig, J., Pinggera, A., Kaur, G., Bock, G., Tuluc, P., L-type Ca(2+) channels in heart and brain. Wiley Interdiscip. Rev. Membr. Transp. Signal 3:2 (2014), 15–38.
135. Lopin, K.V., Gray, I.P., Obejero-Paz, C.A., Thevenod, F., Jones, S.W., Fe(2)(+) block and permeation of CaV3.1 (alpha1G) T-type calcium channels: candidate mechanism for non-transferrin-mediated Fe(2)(+) influx. Mol. Pharmacol. 82:6 (2012), 1194–1204.
136. Tsushima, R.G., Wickenden, A.D., Bouchard, R.A., Oudit, G.Y., Liu, P.P., Backx, P.H., Modulation of iron uptake in heart by L-type Ca2+ channel modifiers: possible implications in iron overload. Circ. Res. 84:11 (1999), 1302–1309.
137. Winegar, B.D., Kelly, R., Lansman, J.B., Block of current through single calcium channels by Fe, Co, and Ni. Location of the transition metal binding site in the pore. J. Gen. Physiol. 97:2 (1991), 351–367.
138. Atar, D., Backx, P.H., Appel, M.M., Gao, W.D., Marban, E., Excitation-transcription coupling mediated by zinc influx through voltage-dependent calcium channels. J. Biol. Chem. 270:6 (1995), 2473–2477.
139. Nasu, T., Murase, H., Shibata, H., Manganese ions penetrate via L-type Ca2+ channels and induce contraction in high-K+ medium in ileal longitudinal muscle of guinea-pig. Gen. Pharmacol. 26:2 (1995), 381–386.
140. Oudit, G.Y., Sun, H., Trivieri, M.G., Koch, S.E., Dawood, F., Ackerley, C., Yazdanpanah, M., Wilson, G.J., Schwartz, A., Liu, P.P., Backx, P.H., L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat. Med. 9:9 (2003), 1187–1194.
141. Crowe, S., Bartfay, W.J., Amlodipine decreases iron uptake and oxygen free radical production in the heart of chronically iron overloaded mice. Biol. Res. Nurs. 3:4 (2002), 189–197.
142. Otto-Duessel, M., Brewer, C., Wood, J.C., Interdependence of cardiac iron and calcium in a murine model of iron overload. Transl. Res. 157:2 (2011), 92–99.
143. Kumfu, S., Chattipakorn, S.C., Fucharoen, S., Chattipakorn, N., Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice. Exp. Physiol. 101:4 (2016), 521–539.
144. Martinez, M.L., Heredia, M.P., Delgado, C., Expression of T-type Ca(2+) channels in ventricular cells from hypertrophied rat hearts. J. Mol. Cell. Cardiol. 31:9 (1999), 1617–1625.
145. Kumfu, S., Chattipakorn, S., Srichairatanakool, S., Settakorn, J., Fucharoen, S., Chattipakorn, N., T-type calcium channel as a portal of iron uptake into cardiomyocytes of beta-thalassemic mice. Eur. J. Haematol. 86:2 (2011), 156–166.
146. Khamseekaew, J., Kumfu, S., Wongjaikam, S., Kerdphoo, S., Jaiwongkam, T., Srichairatanakool, S., Fucharoen, S., Chattipakorn, S.C., Chattipakorn, N., Effects of iron overload, an iron chelator and a T-Type calcium channel blocker on cardiac mitochondrial biogenesis and mitochondrial dynamics in thalassemic mice. Eur. J. Pharmacol. 799 (2017), 118–127.
147. Kumfu, S., Khamseekaew, J., Palee, S., Srichairatanakool, S., Fucharoen, S., Chattipakorn, S.C., Chattipakorn, N., Combined iron chelator and T-type calcium channel blocker exerts greater efficacy on cardioprotection than monotherapy in iron-overload thalassemic mice. Eur. J. Pharmacol. 822 (2018), 43–50.
148. Rosati, B., Yan, Q., Lee, M.S., Liou, S.R., Ingalls, B., Foell, J., Kamp, T.J., McKinnon, D., Robust L-type calcium current expression following heterozygous knockout of the Cav1.2 gene in adult mouse heart. J. Physiol. 589:Pt 13 (2011), 3275–3288.
149. Seisenberger, C., Specht, V., Welling, A., Platzer, J., Pfeifer, A., Kuhbandner, S., Striessnig, J., Klugbauer, N., Feil, R., Hofmann, F., Functional embryonic cardiomyocytes after disruption of the L-type alpha1C (Cav1.2) calcium channel gene in the mouse. J. Biol. Chem. 275:50 (2000), 39193–39199.
150. Fernandes, J.L., Sampaio, E.F., Fertrin, K., Coelho, O.R., Loggetto, S., Piga, A., Verissimo, M., Saad, S.T., Amlodipine reduces cardiac iron overload in patients with thalassemia major: a pilot trial. Am. J. Med. 126:9 (2013), 834–837.
151. Fernandes, J.L., Loggetto, S.R., Verissimo, M.P., Fertrin, K.Y., Baldanzi, G.R., Fioravante, L.A., Tan, D.M., Higa, T., Mashima, D.A., Piga, A., Coelho, O.R., Costa, F.F., Saad, S.T., A randomized trial of amlodipine in addition to standard chelation therapy in patients with thalassemia major. Blood 128:12 (2016), 1555–1561.
152. Sadaf, A., Hasan, B., Das, J.K., Colan, S., Alvi, N., Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia. Cochrane Database Syst. Rev., 7, 2018 (CD011626).
153. Simms, B.A., Zamponi, G.W., Neuronal voltage-gated calcium channels: structure, function, and dysfunction. Neuron 82:1 (2014), 24–45.
154. Mwanjewe, J., Hui, B.K., Coughlin, M.D., Grover, A.K., Treatment of PC12 cells with nerve growth factor increases iron uptake. Biochem. J. 357:Pt 3 (2001), 881–886.
155. Oudit, G.Y., Trivieri, M.G., Khaper, N., Liu, P.P., Backx, P.H., Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. J. Mol. Med. (Berl.) 84:5 (2006), 349–364.
156. Schulla, V., Renstrom, E., Feil, R., Feil, S., Franklin, I., Gjinovci, A., Jing, X.J., Laux, D., Lundquist, I., Magnuson, M.A., Obermuller, S., Olofsson, C.S., Salehi, A., Wendt, A., Klugbauer, N., Wollheim, C.B., Rorsman, P., Hofmann, F., Impaired insulin secretion and glucose tolerance in beta cell-selective Ca(v)1.2 Ca2+ channel null mice. EMBO J. 22:15 (2003), 3844–3854.
157. Mwanjewe, J., Grover, A.K., Role of transient receptor potential canonical 6 (TRPC6) in non-transferrin-bound iron uptake in neuronal phenotype PC12 cells. Biochem. J. 378:Pt 3 (2004), 975–982.
158. Bouron, A., Kiselyov, K., Oberwinkler, J., Permeation, regulation and control of expression of TRP channels by trace metal ions. Pflug. Arch. 467:6 (2015), 1143–1164.
159. Parkes, J.G., Olivieri, N.F., Templeton, D.M., Characterization of Fe2+ and Fe3+ transport by iron-loaded cardiac myocytes. Toxicology 117:2–3 (1997), 141–151.
160. Asard, H., Barbaro, R., Trost, P., Berczi, A., Cytochromesb561: ascorbate-mediated trans-membrane electron transport. Antioxid. Redox Signal. 19:9 (2013), 1026–1035.
161. Ohgami, R.S., Campagna, D.R., McDonald, A., Fleming, M.D., The Steap proteins are metalloreductases. Blood 108:4 (2006), 1388–1394.
162. Ohgami, R.S., Campagna, D.R., Greer, E.L., Antiochos, B., McDonald, A., Chen, J., Sharp, J.J., Fujiwara, Y., Barker, J.E., Fleming, M.D., Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat. Genet. 37:11 (2005), 1264–1269.
163. Knutson, M.D., Steap proteins: implications for iron and copper metabolism. Nutr. Rev. 65:7 (2007), 335–340.
164. Singh, A., Haldar, S., Horback, K., Tom, C., Zhou, L., Meyerson, H., Singh, N., Prion protein regulates iron transport by functioning as a ferrireductase. J. Alzheimers Dis. 35:3 (2013), 541–552.
165. Tripathi, A.K., Haldar, S., Qian, J., Beserra, A., Suda, S., Singh, A., Hopfer, U., Chen, S.G., Garrick, M.D., Turner, J.R., Knutson, M.D., Singh, N., Prion protein functions as a ferrireductase partner for ZIP14 and DMT1. Free Radic. Biol. Med. 84 (2015), 322–330.
166. Haldar, S., Tripathi, A., Qian, J., Beserra, A., Suda, S., McElwee, M., Turner, J., Hopfer, U., Singh, N., Prion protein promotes kidney iron uptake via its ferrireductase activity. J. Biol. Chem. 290:9 (2015), 5512–5522.
167. Davies, P., Moualla, D., Brown, D.R., Alpha-synuclein is a cellular ferrireductase. PLoS One, 6(1), 2011, e15814.
168. McDowall, J.S., Ntai, I., Honeychurch, K.C., Hart, J.P., Colin, P., Schneider, B.L., Brown, D.R., Alpha-synuclein ferrireductase activity is detectible in vivo, is altered in Parkinson's disease and increases the neurotoxicity of DOPAL. Mol. Cell. Neurosci. 85 (2017), 1–11.
169. Miele, M., Fillenz, M., In vivo determination of extracellular brain ascorbate. J. Neurosci. Methods 70:1 (1996), 15–19.
170. Evans, R.M., Currie, L., Campbell, A., The distribution of ascorbic acid between various cellular components of blood, in normal individuals, and its relation to the plasma concentration. Br. J. Nutr. 47:3 (1982), 473–482.
171. Morris, G., Berk, M., Carvalho, A.F., Maes, M., Walker, A.J., Puri, B.K., Why should neuroscientists worry about iron? The emerging role of ferroptosis in the pathophysiology of neuroprogressive diseases. Behav. Brain Res. 341 (2018), 154–175.
172. Stockwell, B.R., Friedmann Angeli, J.P., Bayir, H., Bush, A.I., Conrad, M., Dixon, S.J., Fulda, S., Gascon, S., Hatzios, S.K., Kagan, V.E., Noel, K., Jiang, X., Linkermann, A., Murphy, M.E., Overholtzer, M., Oyagi, A., Pagnussat, G.C., Park, J., Ran, Q., Rosenfeld, C.S., Salnikow, K., Tang, D., Torti, F.M., Torti, S.V., Toyokuni, S., Woerpel, K.A., Zhang, D.D., Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171:2 (2017), 273–285.